Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
Belgium
ItalyIn short
Inflammatory breast cancer is a rare and aggressive form of breast cancer that demands immediate medical attention and a carefully coordinated treatment plan, combining multiple approaches to control disease progression and improve patient outcomes.
When someone receives a diagnosis of inflammatory breast cancer, the focus shifts immediately to stopping the disease in its tracks. This type of cancer is different from many others because it grows and spreads quickly, often in a matter of weeks or months rather than years. The main goal of treatment is to control the cancer's aggressive behavior, reduce symptoms like swelling and redness of the breast, and prevent the disease from spreading further to other parts of the body such as the lungs, liver, or bones.
Treatment decisions depend heavily on several factors that doctors carefully evaluate. The stage of the cancer matters greatly, as inflammatory breast cancer is typically diagnosed at an advanced stage, either stage III or stage IV, depending on whether the cancer has spread only to nearby lymph nodes or to distant organs as well. Doctors also look at the cancer's specific characteristics through biopsy results, checking for special proteins called receptors that can influence how cancer cells grow and which treatments might work best.
Because inflammatory breast cancer is so aggressive, medical guidelines recommend starting treatment right away without delay. The approach is typically multimodal, meaning it combines different types of treatment working together. Standard care approved by medical organizations involves a step-by-step plan that usually starts with medications to shrink the cancer, followed by surgery to remove it, and then additional therapy to reduce the chance of it coming back.
At the same time, researchers around the world are working on new therapies being tested in clinical trials. These investigational treatments aim to target the unique biological features of inflammatory breast cancer that make it so difficult to treat with current methods. Patients may have the opportunity to participate in these studies, which offer access to cutting-edge approaches that could potentially improve outcomes.
The established treatment plan for inflammatory breast cancer follows a carefully designed sequence that has been refined over years of clinical experience. Medical societies and cancer treatment guidelines recommend what doctors call a trimodal approach, meaning three main types of therapy are used one after the other.
The first step is usually neoadjuvant chemotherapy, which means giving chemotherapy before surgery. This approach serves several important purposes. The main goal is to shrink the tumor and reduce the inflammation in the breast, making surgery more effective. Chemotherapy at this stage also starts fighting any cancer cells that may have already begun spreading to other parts of the body, even if they cannot yet be detected on scans.
The chemotherapy regimen typically involves a combination of drugs given through an intravenous line over several months. Doctors select specific combinations based on proven effectiveness against aggressive breast cancers. Common side effects include fatigue, nausea, hair loss, increased risk of infections due to lower white blood cell counts, and changes in appetite. Many of these side effects can be managed with supportive medications and nutritional guidance from the care team.
For patients whose cancer cells have a protein called HER2 on their surface, doctors add a type of medication known as targeted therapy alongside chemotherapy. HER2-positive cancers represent a significant portion of inflammatory breast cancer cases. The most commonly used targeted drug is trastuzumab (also known by the brand name Herceptin), which specifically attaches to the HER2 protein and blocks signals that tell cancer cells to grow and divide.
This combination of chemotherapy and targeted therapy has been shown to improve outcomes in patients with HER2-positive inflammatory breast cancer. The targeted therapy is usually continued for a full year of treatment, extending beyond the chemotherapy and surgery phases. Side effects of HER2-targeted drugs are generally milder than chemotherapy and may include heart function changes, so doctors monitor the heart carefully during treatment.
After completing chemotherapy and targeted therapy if indicated, the next step is surgery. For inflammatory breast cancer, doctors almost always recommend a mastectomy, which means removing the entire breast. This is different from a lumpectomy, which only removes part of the breast. The reason for complete breast removal is that inflammatory breast cancer affects the skin and lymphatic vessels throughout the breast, not just one specific area.
During the same operation, surgeons typically remove lymph nodes from under the arm (called axillary lymph node dissection) to check whether cancer has spread there and to reduce the risk of it returning. Some patients may be candidates for breast reconstruction, either at the time of mastectomy or later. This decision involves discussions with both the cancer surgeon and a plastic surgeon about the timing and type of reconstruction that would be safest and most appropriate.
Following surgery and recovery, patients receive radiotherapy to the chest wall area where the breast was removed and usually to the lymph node areas as well. Radiation uses high-energy beams to kill any remaining cancer cells that might not have been removed during surgery. This step is considered essential in inflammatory breast cancer because of the high risk that microscopic cancer cells remain in the tissue.
Radiation therapy is typically given five days a week for several weeks. Each treatment session lasts only a few minutes, though the overall appointment time is longer due to setup. Side effects usually include skin changes in the treated area, such as redness, dryness, or darkening, similar to a sunburn. Fatigue is also common during radiation treatment. These effects generally improve within weeks to months after treatment ends.
If the cancer cells have hormone receptors, meaning they use estrogen or progesterone to grow, patients receive hormone therapy for several years after completing other treatments. However, it's important to note that many inflammatory breast cancers are hormone receptor negative, meaning these drugs won't be effective. For those whose cancers do have hormone receptors, medications like tamoxifen or aromatase inhibitors are prescribed.
These medications work by blocking the effects of estrogen on cancer cells or reducing the amount of estrogen the body makes. Hormone therapy is taken as a daily pill, usually for five to ten years. Side effects vary depending on the specific medication but may include hot flashes, joint pain, bone thinning, and mood changes. The benefit is that hormone therapy significantly reduces the risk of cancer returning.
While standard treatment has improved outcomes for inflammatory breast cancer patients, the disease remains challenging to cure, and many patients experience recurrence. This has driven intensive research efforts to find more effective therapies. Clinical trials are studies where new treatments are tested carefully to see if they are safe and work better than current options.
Clinical trials move through different phases, each with a specific purpose. Phase I trials test a new treatment in a small group of people to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more patients and focus on whether the treatment actually works against the cancer while continuing to monitor safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to see if the new approach is better, equal, or not as good.
One promising area of research involves immunotherapy, which harnesses the body's own immune system to fight cancer. Scientists have discovered that inflammatory breast cancer has unique characteristics that might make it vulnerable to certain immune-based treatments. Some trials are testing drugs called checkpoint inhibitors, which remove the brakes that cancer cells put on immune cells, allowing the immune system to attack the tumor more effectively.
These immunotherapy drugs work by targeting specific molecules on immune cells or cancer cells. For example, some drugs block a protein called PD-1 or PD-L1, which cancer cells use to hide from the immune system. Early results from studies testing these drugs in combination with chemotherapy have shown promise in some patients, with tumors shrinking more than with chemotherapy alone. However, not all patients respond to immunotherapy, and researchers are working to identify which patients are most likely to benefit.
Scientists studying the biology of inflammatory breast cancer have identified several molecular pathways that drive its aggressive behavior. This has led to the development of targeted drugs designed to block these specific pathways. Some investigational therapies being tested target growth factor receptors beyond HER2, while others target proteins involved in cancer cell survival and spread.
For instance, some trials are exploring drugs that block a family of proteins called kinases, which send growth signals inside cancer cells. These kinase inhibitors can potentially stop cancer cells from multiplying and spreading. Other studies are testing drugs that target the blood vessels feeding the tumor, cutting off its nutrient supply. These are called anti-angiogenic drugs.
Inflammatory breast cancers that lack hormone receptors and HER2 (called triple-negative) are particularly difficult to treat because they don't respond to hormone therapy or HER2-targeted drugs. Researchers are especially focused on finding new options for these patients. Clinical trials are testing various combinations of chemotherapy with immunotherapy or with other novel agents.
Some studies are also exploring whether certain chemotherapy drugs work better when combined with new experimental medications that target DNA repair mechanisms in cancer cells. The theory is that cancer cells with already damaged DNA repair systems will be unable to survive when additional stress is placed on them.
Clinical trials for inflammatory breast cancer are being conducted at major cancer centers throughout the United States, Europe, and other regions around the world. Patients interested in participating should discuss this option with their oncology team. Eligibility depends on factors such as the stage of cancer, previous treatments received, overall health, and the specific characteristics of the cancer cells.
Participating in a clinical trial means receiving close monitoring and access to potentially beneficial new treatments before they become widely available. All participants continue to receive the best available standard care along with the experimental treatment being studied. The decision to join a trial is entirely voluntary, and patients can withdraw at any time.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
